News Summary
PositiveInsmed delivered strong Q2 2026 earnings with significant upside beats (EPS +24.64%, revenue +9.18%) and substantially raised peak revenue guidance across its pipeline—BRINSUPRI to >$7B, TPIP to >$6B, and ARIKAYCE >$1B—while also raising full-year 2026 BRINSUPRI revenue guidance to $1.25-1.40B. The FDA granted Priority Review for ARIKAYCE's expanded MAC lung disease indication (PDUFA January 28, 2027), representing a material regulatory milestone for market expansion.
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 2.2M | +2.2M | $229M | 2.1% | — | NEW |
| Duquesne Family Office | Stanley Druckenmiller | 1.4M | +271K | $152M | 3.5% | +23% | Existing |
| Point72 | Steve Cohen | 537K | +537K | $57M | <0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where INSM ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #4 of this fund's book
- 1Natera Inc$865M
- 2Taiwan Semiconductor Manufac$282M
- 3Stmicroelectronics N V$232M
- 4Insmed Inc$152M
- 5Ypf Sociedad Anonima$143M
- 6Amazon Com Inc$129M
- 7Bbb Foods Inc$121M
position #23 of this fund's book
- 20MONSTER BEVERAGE CORP NEW$253M
- 21DPC HOLDINGS PLC$252M
- 22SNOWFLAKE INC$249M
- 23INSMED INC$229M
- 24SHERWIN WILLIAMS CO$198M
- 25CAMDEN PPTY TR$195M
- 26VULCAN MATLS CO$188M
Values are quarter-end position sizes. Shown only for funds where INSM ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| Brennan David R | — | SELL | 25K | $124.00 | $3.10M | 2026-09-09 | ↗ |
| SHAROKY MELVIN MD | — | SELL | 5K | $127.53 | $0.64M | 2026-08-17 | ↗ |
| Adsett Roger | Chief Operating Officer | SELL | 240K | $133.27 | $31.96M | 2026-08-10 | ↗ |
| Flammer Martina M.D. | Chief Medical Officer | SELL | 9K | $127.00 | $1.13M | 2026-08-06 | ↗ |
| Flammer Martina M.D. | Chief Medical Officer | SELL | 18K | $129.40 | $2.37M | 2026-08-06 | ↗ |
| Lewis William | Chair and CEO | SELL | 5K | $105.62 | $0.51M | 2026-07-23 | ↗ |
| Lewis William | Chair and CEO | SELL | 6K | $106.43 | $0.62M | 2026-07-23 | ↗ |
| Lewis William | Chair and CEO | SELL | 5K | $116.55 | $0.58M | 2026-07-09 | ↗ |
| Lewis William | Chair and CEO | SELL | 2K | $117.62 | $0.27M | 2026-07-09 | ↗ |
| Lewis William | Chair and CEO | SELL | 3K | $118.52 | $0.40M | 2026-07-09 | ↗ |
| Flammer Martina M.D. | Chief Medical Officer | SELL | 5K | $109.02 | $0.53M | 2026-07-06 | ↗ |
| Flammer Martina M.D. | Chief Medical Officer | SELL | 7K | $110.60 | $0.82M | 2026-07-06 | ↗ |
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| Darwin Global Management, Ltd. | SC 13G/A | 6.4M | 3.0% | 2026-08-14 | ↗ |
| FMR LLC | SC 13G/A | 16.1M | 7.4% | 2026-08-06 | ↗ |
| JPMORGAN CHASE & CO. | SC 13G/A | 10.4M | 4.7% | 2026-07-22 | ↗ |
| Darwin Global Management, Ltd. | SC 13G/A | 16.8M | 7.8% | 2026-05-15 | ↗ |
| FMR LLC | SC 13G | 13.1M | 6.1% | 2026-05-06 | ↗ |
| Vanguard Capital Management | SC 13G | 11.5M | 5.3% | 2026-04-30 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.